This phenomenon partially explains the observed poor outcomes of classic HER2-targeted therapies in the setting of NSCLC than in breast cancer, where its oncogenesis predominantly relies on HER2 overexpression attributed to gene amplification. The gene discussed is ERBB2; the disease is breast carcinoma.